Legal & General Group Plc “major institutional investor of Immupharma Plc” Tim McCarthy

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has told DirectorsTalk that it has received notification by Legal & General Group Plc (“L&G”) confirming its holding in ImmuPharma of 4,285,714 million Ordinary Shares in the capital of the Company, representing 3.43% of ImmuPharma’s total voting rights.

Commenting, Tim McCarthy, Chairman of ImmuPharma, said: “We are delighted to be able to disclose Legal & General as one of the new significant and major institutional investors which participated in ImmuPharma’s recent successful vendor placing. One of the Board’s priorities is to maintain and strengthen our shareholder base. We are therefore delighted that such a highly regarded institution as Legal & General has demonstrated its support for ImmuPharma.”

Full disclosure of the TR1 is shown below:

 
 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 
-------------------------------------------------------------------------------------------------- 
 
 1. Identity of the issuer or                                            Immupharma Plc 
  the underlying issuer 
  of existing shares to which 
  voting rights are 
  attached: 
------------------------------------------------------------  ------------------------------------ 
 2. Reason for the notification (please tick the appropriate 
  box or boxes): 
-------------------------------------------------------------------------------------------------- 
 An acquisition or disposal of voting rights                                                   Yes 
--------------------------------------------------------------------------------------------  ---- 
 
   An acquisition or disposal of qualifying financial 
   instruments which may result in the acquisition 
   of shares already issued to which voting rights 
   are attached. 
--------------------------------------------------------------------------------------------  ---- 
 
   An acquisition or disposal of instruments with 
   similar economic effect to qualifying financial 
   instruments 
--------------------------------------------------------------------------------------------  ---- 
 An event changing the breakdown of voting rights                                              Yes 
--------------------------------------------------------------------------------------------  ---- 
 Other (please                                             Placement of 2,857,143 shares 
  specify): 
--------------------------------------------------------  ----------------------------------  ---- 
 3. Full name of person(s)                                         Legal & General Group Plc 
  subject to the                                                             (L&G) 
  notification obligation: 
----------------------------------------------------------  -------------------------------------- 
 4. Full name of shareholder(s) 
  (if different from 3.):                                           Legal & General Assurance 
                                                                  Society Limited (LGAS & LGPL) 
----------------------------------------------------------  -------------------------------------- 
                                                                        21 October 2016 
   5. Date of the transaction 
   and date on 
   which the threshold is 
   crossed or 
   reached: 
----------------------------------------------------------  -------------------------------------- 
 6. Date on which issuer                                                28 October 2016 
  notified: 
----------------------------------------------------------  -------------------------------------- 
 7. Threshold(s) that is/are                                            L&G (Above 3%) 
  crossed or 
  reached: 
----------------------------------------------------------  -------------------------------------- 
 
 
 
 8. Notified details: 
-------------------------------------------------------------------------------------------------------------------------------- 
 A: Voting rights attached to shares 
-------------------------------------------------------------------------------------------------------------------------------- 
 Class/type                  Situation previous                                   Resulting situation after the 
 of                           to the triggering                                       triggering transaction 
 shares                          transaction 
 
 if possible 
 using 
 the ISIN 
 CODE 
------------  ------------------------------------------------  ---------------------------------------------------------------- 
                   Number                   Number                                  Number of voting            % of voting 
                     of                       of                                          rights                   rights 
                   Shares                   Voting 
                                            Rights 
------------  ----------------  ------------------------------                 --------------------------  --------------------- 
                                                                    Number         Direct       Indirect     Direct    Indirect 
                                                                  of shares 
------------      ------------      ------------  ------------  -------------  -------------  -----------  ---------  ---------- 
 ORD GBP                     First notification 
  0.10                       under DTR Sourcebook                  4,285,714      4,285,714        -         3.43%         - 
------------  ------------------------------------------------  -------------  -------------  -----------  ---------  ---------- 
 
 B: Qualifying Financial Instruments 
-------------------------------------------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
-------------------------------------------------------------------------------------------------------------------------------- 
                                                                                  Number of voting 
  Type of            Expiration        Exercise/                                   rights that                  % of voting 
  financial          date              Conversion                                  may be                       rights 
  instrument                           Period                                      acquired if 
                                                                                   the 
                                                                                   instrument 
                                                                                   is 
                                                                                   exercised/ 
                                                                                   converted. 
----------------  ----------------  -------------------------------------------  --------------------------  ------------------- 
 
 
 C: Financial Instruments with similar economic effect 
  to Qualifying Financial Instruments 
-------------------------------------------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
-------------------------------------------------------------------------------------------------------------------------------- 
 
  Type of          Exercise         Expiration       Exercise/       Number of voting              % of voting 
  financial        price            date             Conversion      rights instrument             rights 
  instrument                                         period          refers to 
--------------  ----------------  --------------  --------------  ----------------------------  -------------------------------- 
                                                                                                       Nominal           Delta 
--------------  ----------------  --------------  --------------  ----------------------------  --------------------  ---------- 
 
 
 Total (A+B+C) 
-------------------------------------------------------------------------------------------------------------------------------- 
 Number of voting rights                                           Percentage of voting rights 
----------------------------------------------------------------  -------------------------------------------------------------- 
 
                             4,285,714                                                         3.43% 
----------------------------------------------------------------  -------------------------------------------------------------- 
 
 
 
 9. Chain of controlled undertakings through which the 
  voting rights and/or the 
  financial instruments are effectively held, if applicable: 
-------------------------------------------------------------------------------------------------------------------- 
                                                                               Legal & General Group Plc (Direct and 
                                                                                 Indirect) (Group) (Below 5% = Total 
                                                                                                           Position) 
                                                                               Legal & General Investment Management 
                                                                              (Holdings) Limited (LGIMH) (Direct and 
                                                                                                    Indirect) (Below 
                                                                                                5% = Total Position)
                                                                               Legal & General Investment Management 
                                                                         Limited (Indirect) (LGIM) (Below 5% = Total 
                                                                                                           Position) 
                                      Legal & General Group Plc (Direct) (L&G) (4,285,714, 3.43% = LGAS, LGPL & PMC) 
                              Legal & General Investment Management       Legal & General Insurance Holdings Limited 
                              (Holdings) Limited (Direct) (LGIMHD)        (Direct) (LGIH) (4,285,714, 3.43% = LGAS & 
                                                                                                               LGPL) 
                               Legal & General Assurance (Pensions         Legal & General Assurance Society Limited 
                                Management) Limited (PMC)                   (LGAS & LGPL) (4,285,714, 3.43% = LGAS & 
                                                                                                               LGPL) 
                                                                           Legal & General Pensions Limited (Direct) 
                                                                                                              (LGPL)
Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    Learning About Lupus

    May is Lupus Awareness Month. It is a disease that is relatively common in the Caribbean yet many of us are unfamiliar with the condition. Lupus is an autoimmune condition that can affect almost every system

    Immupharma Plc

    ImmuPharma Change of Registered Office Address

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7BL.

    Immupharma Plc

    ImmuPharma Change of AGM Venue

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, today announced that the Company’s Annual General Meeting confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden, London SW1W 0AU. The COVID-19

    Immupharma Plc

    Lupus Latest Facts: Causes, Symptoms and Treatments

    Lupus is a relatively rare inflammatory disease. In the US 1.5 million are currently living with the condition. It is an autoimmune disease that can affect various organs including the skin, joints, kidneys, and brain. What

    Immupharma Plc

    Selena Gomez urges fans to join the fight against Lupus

    US singer Selena Gomez has urged her fans across the world to join the fight against Lupus, an autoimmune disease. The disease leads to the body’s immune system becoming hyperactive, attacking normal and healthy tissues. On

    Immupharma Plc

    Understanding Lupus

    Lupus is a chronic (long-term) disease that can cause inflammation and pain in any part of your body. It’s an autoimmune disease, which means that your immune system — the body system that usually fights infections

    Immupharma Plc

    What to know about COVID-19 and lupus

    Lupus is a chronic autoimmune condition in which the immune system attacks its own tissues. People with lupus are at higher risk of infections, and those with lupus who develop COVID-19 may be at higher risk

    Immupharma Plc

    Frequently asked questions: coronavirus (COVID-19) and lupus

    Our Health Educator Network—health-care professionals and lupus specialists who provide individualized answers—have seen their inquires triple in the last week. The following are questions they’ve been frequently asked and their answers. Should I wear a facemask?

    Immupharma Plc

    Are People with Lupus Protected Against COVID-19?

    There is no evidence that taking hydroxychloroquine (Plaquenil) is effective in preventing a person from contracting the coronavirus (COVID-19). People with lupus should follow the guidance of their doctor and the safety guidelines being issued by

    Immupharma Plc

    Dr Miriam Stoppard on Lupus

    Lupus isn’t that common but when it strikes it can be very ­serious, even life-threatening. The story of the singer and ­actress Selena Gomez is a case in point. All lupus sufferers will be grateful to her because